The country completes 5 drug negotiations, dropping 50%

Yesterday, Li Bin, deputy director of the National Health and Design Commission, deputy director Ma Xiaowei and deputy director Wang Peian answered questions from reporters on the two-child policy, grading diagnosis and treatment, drug price negotiation and other topics at the Beijing Media Center and introduced the contents of the national drug price negotiations. disclose:

Now that we have carried out the pilot negotiations, we have selected several varieties, which are roughly five or so varieties, including medicines related to cancer treatment and related to other major diseases. The prices are more expensive and more expensive. After negotiating on medicine, the effect of negotiations should be relatively ideal, with a large drop, which can be reduced to more than 50% in general.

At the same time, Ma Xiaowei said: “We are highly concerned about import issues and price issues of patented drugs, and we may achieve some breakthroughs in this regard. Once the drug negotiations are successful, we will consider including the relevant drug reimbursement catalog to make the price of this drug. There can be a relatively large drop."

According to the report of the public platform medicine point of the "Health News" under the supervision of the National Health and Family Planning Commission, it was reported at the end of last year:

Recently, as an important part of the new mechanism for the procurement of drugs in public hospitals, the trials of national drug price negotiations for patented drugs and exclusive production of drugs were officially launched. Five drugs involving three diseases were included in the first pilot trials, namely lenalidomide (Sinkidamine) for the treatment of multiple myeloma; tenofovir disoproxil (Glidide) for the treatment of hepatitis B; Gefitinib (AstraZeneca), erlotinib (Roche), and ecritinib (Zhejiang Beida) for cell lung cancer. The results of this negotiation will begin in 2016.

The following is the specific content of the interview:

[Reporter of CCTV, CCTV, and CCTV News]: Today is the March 8th Women’s Day. We would also like to wish Li Bin’s director a happy holiday and wish the live female friends a happy holiday. My problem is related to medicine. Last year, one person bought an imitation anticancer drug from India for a patient suffering from leukemia. Later, this person almost ate the lawsuit. We would like to know if there is an urgent need for such patients, but there is no way to produce life-saving drugs in the country, from the point of view of the Health and Planning Commission, is there any good solution to enable these patients to receive timely and effective relief? Thank you.

[Li Bin] You are talking about medicine, but in fact you mentioned a deep-seated problem that is to promote the medical reform to require the linkage of three doctors. That is to say, medical care, medicine, and medical insurance must be linked by three doctors. This is also the prime minister. In the 2016 task set forth in this year’s report, on how to satisfy people's drug use, and in particular to solve the problem that some patented drugs are expensive, people are unable to afford it. We are taking some measures, including accepting some of our representatives and members. The proposed proposal is to carry out national negotiations.

Now that we have carried out the pilot negotiations, we have selected several varieties, which are roughly five or so varieties, including medicines related to cancer treatment and related to other major diseases. The prices are more expensive and more expensive. After negotiating on medicine, the effect of negotiations should be relatively ideal, with a large drop, which can be reduced to more than 50% in general.

We are now in the final connection. Drugs and medical insurance must also be well connected. After the finalization of convergence, we will announce to the public that the drug is currently at this price, which will greatly ease the burden on the people in using drugs in this area. Including some of the medicines mentioned by everyone that mention more cancers. The following specific I would like to ask Mr. Xiaowei to give a lecture.

[Ma Xiaowei]: Director Li has already fully answered this question. We are highly concerned about the issue of import of patented drugs and price issues. Some breakthroughs may be made in this regard. Once the drug negotiations are successful, we will consider including the relevant drug reimbursement list, so that the price of this drug can have a relatively substantial decline.

At the same time, we are also concerned that after the implementation of major illness insurance in the country, there are 20 kinds of diseases to be further compensated, and in the process of compensation, the issue of the simultaneous need for patented drugs and generic drugs was discovered. Therefore, while negotiating price cuts, we also paid attention to the domestic research and development of generic drugs, localization, and the one-time evaluation of the effectiveness of generic drugs. We are also considering the opening of some special drugs to open green channels and implement rapid import. Measures. In short, we must do our utmost to solve the problems of drugs that are difficult to buy and expensive to use, and strive to solve the problem of drugs during the “13th Five-Year Plan” period.